Text Size: a  |   a 

Chronic Lyme Disease Could be at the Root of MS

July 6, 2016

The worldwide prevalence of multiple sclerosis parallels that of the Lyme disease pathogen, Borrelia (B.) burgdorferi. Specifically in America and Europe, the birth excesses of those who develop MS later in life mirror the exact seasonal distributions of the lxodes ticks that transmit Borrelia. It has been found by researchers that there is no other disease that displays equally marked epidemiological clusters by season and locality. This supports the hope that prevention of this may in fact be attainable.

Minocycline, tinidazole and hydroxychloroquine have been reported capable of destroying the spirochaetal and cystic L-form of B. burgdorferi that is found in the brains of MS patients, because of this there is even more new hope for those that are already effected by the illness.

The Jarisch Herxheimer reaction that is triggered by decaying Borrelia at treatment initiation can be reduced by the immunomodulating anti-inflammatory potential of minocycline and hydroxychloroquine. While there are also cases unrelated to B. burgdorferi, minocycline is known for the beneficial effect it has on several factors that are considered to be detrimental to those with MS.

Patients that receive a combination of these pharmaceuticals are expected to be cured or have a longer remission period in comparison to the untreated controls.

In order to approach this scientifically, there must be a randomized, prospective, double-blinded trial in patients from B. burgdorferi endemic areas with MS and/or Borrelia L-forms in their cerebrospinal fluid and they must yield reasonable significance. This must be done even though this cost-effective and potentially curative treatment seems simple enough.